

# John Buse

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7048183/john-buse-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

512  
papers

86,457  
citations

118  
h-index

291  
g-index

555  
ext. papers

99,940  
ext. citations

11.6  
avg, IF

8.04  
L-index

#	Paper	IF	Citations
512	Effects of intensive glucose lowering in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2545-59	59.2	5809
511	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 644-657	59.2	3789
510	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 311-22	59.2	3606
509	Follow-up report on the diagnosis of diabetes mellitus. <i>Diabetes Care</i> , <b>2003</b> , 26, 3160-7	14.6	2996
508	Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2012</b> , 35, 1364-79	14.6	2713
507	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1834-1844	59.2	2547
506	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32, 193-203	14.6	2432
505	Effects of intensive blood-pressure control in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1575-85	59.2	2411
504	International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32, 1327-34	14.6	2152
503	Effects of combination lipid therapy in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1563-74	59.2	1940
502	Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 140-9	14.6	1906
501	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 232-42	59.2	1739
500	The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2005</b> , 28, 2289-304	14.6	1574
499	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2018</b> , 41, 2669-2701	14.6	1307
498	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). <i>Lancet, The</i> , <b>2009</b> , 374, 39-47	40	1178
497	Strategies for multivessel revascularization in patients with diabetes. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2375-84	59.2	1140
496	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , <b>2012</b> , 55, 1577-96	10.3	1108

495	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27, 2628-35	14.6	1088
494	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1228-1239	59.2	1017
493	Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 1963-72	14.6	935
492	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 419-30	40	914
491	Effects of medical therapies on retinopathy progression in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 233-44	59.2	859
490	Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. <i>Lancet, The</i> , <b>2008</b> , 372, 1240-50	40	848
489	Molecular biology of mammalian glucose transporters. <i>Diabetes Care</i> , <b>1990</b> , 13, 198-208	14.6	755
488	Long-term effects of intensive glucose lowering on cardiovascular outcomes. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 818-28	59.2	732
487	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1659-68	27.4	721
486	How do we define cure of diabetes?. <i>Diabetes Care</i> , <b>2009</b> , 32, 2133-5	14.6	696
485	Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). <i>Diabetes Care</i> , <b>2009</b> , 32, 1224-30	14.6	691
484	The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. <i>BMJ, The</i> , <b>2010</b> , 340, b4909	5.9	672
483	Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 311-20	59.2	664
482	A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. <i>Diabetes Care</i> , <b>2005</b> , 28, 1547-54	14.6	664
481	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , <b>2018</b> , 61, 2461-2498	10.3	656
480	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1321-31	59.2	654
479	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 839-848	59.2	599
478	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 275-86	2.5	591

477	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Circulation</i> , <b>2007</b> , 115, 114-26	16.7	552
476	Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 1547-55	27.4	547
475	Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2009</b> , 52, 17-30	10.3	541
474	Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 8260-5	11.5	509
473	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 431-9	40	503
472	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Diabetes Care</i> , <b>2008</b> , 31, 137-50	14.6	500
471	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , <b>2015</b> , 38, 1687-93	14.6	499
470	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2015</b> , 58, 429-42	10.3	496
469	Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1477-90	59.2	493
468	Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 3082-9	5.6	487
467	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2020</b> , 43, 487-493	14.6	483
466	The prevention or delay of type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 742-9	14.6	452
465	Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. <i>Archives of Internal Medicine</i> , <b>2002</b> , 162, 1568-76		432
464	The soluble interleukin-6 receptor is generated by shedding. <i>European Journal of Immunology</i> , <b>1993</b> , 23, 473-80	6.1	410
463	Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 103-12	8	405
462	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , <b>2007</b> , 30, 162-72	14.6	405
461	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. <i>Lancet, The</i> , <b>2013</b> , 381, 117-24	40	397
460	Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 21i-33i	3	385

459	The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. <i>Science</i> , <b>1986</b> , 231, 733-5	33.3	383
458	Effect of nateglinide on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1463-76	59.2	358
457	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. <i>Lancet Neurology</i> , <b>2011</b> , 10, 969-77	24.1	356
456	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 723-732	59.2	349
455	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 105-113	18.1	336
454	Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. <i>Diabetes Care</i> , <b>2010</b> , 33, 983-90	14.6	331
453	The T1D Exchange clinic registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 4383-9	5.6	328
452	The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2005</b> , 48, 1684-99	10.3	307
451	Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. <i>Journal of Biological Chemistry</i> , <b>1989</b> , 264, 7776-9	5.4	307
450	Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. <i>Diabetes Care</i> , <b>2013</b> , 36, 2035-7	14.6	304
449	Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2006</b> , 49, 1711-21	10.3	303
448	DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. <i>Diabetes Care</i> , <b>2010</b> , 33, 1255-61	14.6	274
447	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 298-304	15.1	272
446	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Circulation</i> , <b>2008</b> , 118, 255-7	16.7	265
445	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. <i>Diabetes Care</i> , <b>2018</b> , 41, 14-31	14.6	263
444	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. <i>Lancet</i> , <b>2012</b> , 379, 1489-97	40	260
443	Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. <i>Diabetes Care</i> , <b>2005</b> , 28, 337-442	14.6	260
442	Glucose measurement: confounding issues in setting targets for inpatient management. <i>Diabetes Care</i> , <b>2007</b> , 30, 403-9	14.6	257

441	A school-based intervention for diabetes risk reduction. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 443-53	59.2	251
440	Recommendations for management of diabetes during Ramadan: update 2010. <i>Diabetes Care</i> , <b>2010</b> , 33, 1895-902	14.6	250
439	Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 885-93	18.1	237
438	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 438-50	3.5	235
437	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , <b>2020</b> , 63, 221-228	10.3	235
436	Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. <i>Diabetes Care</i> , <b>2010</b> , 33, 428-33	14.6	232
435	Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2008</b> , 31, 173-5	14.6	232
434	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2337-2348	59.2	224
433	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 275-286	2.5	217
432	Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 3411-9	5.6	211
431	Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. <i>Diabetes Care</i> , <b>2007</b> , 30, 2399-400	14.6	211
430	HO-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery. <i>ACS Nano</i> , <b>2017</b> , 11, 613-620	16.7	201
429	Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. <i>Pediatrics</i> , <b>2015</b> , 135, 424-34	7.4	193
428	Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). <i>Diabetes Care</i> , <b>2014</b> , 37, 2926-33	14.6	189
427	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. <i>Lancet, The</i> , <b>2010</b> , 375, 1365-74	40	188
426	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , <b>2016</b> , 39, 198-205	14.6	182
425	1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 1214-9	14.6	182
424	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 1016-27	6.7	180

423	Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 1721-8	14.6	179
422	Effect of alogliptazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 1515-25	27.4	177
421	Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2013</b> , 159, 1-12	8	177
420	Recommendations for management of diabetes during Ramadan. <i>Diabetes Care</i> , <b>2005</b> , 28, 2305-11	14.6	175
419	Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <i>Diabetes Care</i> , <b>2013</b> , 36, 2254-61	14.6	173
418	Hypoxia and HO Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery. <i>Nano Letters</i> , <b>2017</b> , 17, 733-739	11.5	172
417	A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. <i>Journal of Clinical Epidemiology</i> , <b>2003</b> , 56, 164-70	5.7	167
416	Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs. <i>Nature Biomedical Engineering</i> , <b>2020</b> , 4, 499-506	19	166
415	Effects of rosiglitazone, glyburide, and metformin on $\beta$ cell function and insulin sensitivity in ADOPT. <i>Diabetes</i> , <b>2011</b> , 60, 1552-60	0.9	164
414	Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 1689-94	5.6	163
413	Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 823-30.e5	4.9	162
412	Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 1154-62	5.6	161
411	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 126-35	16.2	161
410	Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. <i>Lancet, The</i> , <b>2017</b> , 389, 369-380	4.0	158
409	Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 4i-20i	3	155
408	Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. <i>Diabetes Care</i> , <b>2010</b> , 33, 1300-3	14.6	153
407	Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. <i>Diabetes Care</i> , <b>2007</b> , 30, 2458-64	14.6	149
406	Human intestinal glucose transporter expression and localization of GLUT5. <i>American Journal of Physiology - Cell Physiology</i> , <b>1992</b> , 262, C795-800	5.4	147

405	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , <b>2019</b> , 42, 1147-1154	14.6	138
404	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 1181-8	14.6	138
403	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 898-907	27.4	138
402	Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery. <i>Advanced Materials</i> , <b>2016</b> , 28, 3115-3121	24	138
401	Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. <i>American Heart Journal</i> , <b>2008</b> , 155, 215-23	4.9	137
400	Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery. <i>ACS Nano</i> , <b>2018</b> , 12, 2466-2473	16.7	132
399	The safety of incretin-based therapies--review of the scientific evidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2027-31	5.6	130
398	Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. <i>Diabetes Technology and Therapeutics</i> , <b>2003</b> , 5, 355-63	8.1	129
397	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , <b>2016</b> , 39, 701-8	14.6	126
396	Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 990-1004	27.4	122
395	Advances in transdermal insulin delivery. <i>Advanced Drug Delivery Reviews</i> , <b>2019</b> , 139, 51-70	18.5	119
394	Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States. <i>Journal of Pediatrics</i> , <b>2015</b> , 167, 627-32.e1-4	3.6	118
393	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , <b>2018</b> , 41, 1970-1980	14.6	117
392	Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2585-2597	6.7	115
391	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , <b>2013</b> , 36, 1779-88	14.6	114
390	Development and validation of the Diabetes Numeracy Test (DNT). <i>BMC Health Services Research</i> , <b>2008</b> , 8, 96	2.9	113
389	Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes. <i>Journal of Clinical Investigation</i> , <b>1994</b> , 93, 578-85	15.9	113
388	Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 324-33	11.5	112



387	Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 191ra82	17.5	112
386	Synthetic beta cells for fusion-mediated dynamic insulin secretion. <i>Nature Chemical Biology</i> , <b>2018</b> , 14, 86-93	11.7	110
385	The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2004</b> , 6, 133-56	6.7	110
384	Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin. <i>Biomacromolecules</i> , <b>2014</b> , 15, 3495-502	6.9	109
383	Prevention or delay of type 2 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27 Suppl 1, S47-54	14.6	108
382	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 91, 1667-700	5.6	106
381	Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 528-539	18.1	105
380	DURability of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32, 1007-13	14.6	103
379	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). <i>Diabetologia</i> , <b>2018</b> , 61, 48-57	10.3	101
378	Red Blood Cells for Glucose-Responsive Insulin Delivery. <i>Advanced Materials</i> , <b>2017</b> , 29, 1606617	24	100
377	One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 965-73	6.7	100
376	Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. <i>Environmental Health Perspectives</i> , <b>2008</b> , 116, 1666-74	8.4	99
375	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 370-380	16.2	98
374	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , <b>2018</b> , 61, 58-65	10.3	98
373	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1693-701	14.6	98
372	The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 1067-74	14.6	96
371	Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. <i>Diabetes and Vascular Disease Research</i> , <b>2011</b> , 8, 237-40	3.3	92
370	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , <b>2016</b> , 39, 603-10	14.6	90

369	Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. <i>Diabetes Care</i> , <b>2012</b> , 35, 1008-14	14.6	88
368	Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses. <i>Journal of Experimental Medicine</i> , <b>1984</b> , 159, 1629-36	16.6	88
367	Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation. <i>Advanced Materials</i> , <b>2020</b> , 32, e1902004	24	87
366	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , <b>2016</b> , 39, 1186-201	14.6	86
365	Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. <i>Diabetes Care</i> , <b>2011</b> , 34, 2403-5	14.6	86
364	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 1181-95	3.5	84
363	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 2262-2271	14.6	82
362	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2532-2540	6.7	81
361	Bioresponsive Microneedles with a Sheath Structure for H O and pH Cascade-Triggered Insulin Delivery. <i>Small</i> , <b>2018</b> , 14, e1704181	11	80
360	Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. <i>Diabetologia</i> , <b>2008</b> , 51, 8-11	10.3	80
359	A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience. <i>Pediatric Diabetes</i> , <b>2014</b> , 15, 110-7	3.6	79
358	A Special Thanks to the Reviewers of Diabetes Care. <i>Diabetes Care</i> , <b>2020</b> , 43, 939-939	14.6	78
357	The role of the human placenta in the transfer and metabolism of insulin. <i>Journal of Clinical Investigation</i> , <b>1962</b> , 41, 29-41	15.9	76
356	Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 920-929	11.5	75
355	Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(1) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. <i>Diabetic Medicine</i> , <b>2013</b> , 30, 1293-7	3.5	74
354	Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 42-54	6.7	74
353	Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. <i>Diabetes Care</i> , <b>1998</b> , 21, 1455-61	14.6	73
352	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. <i>American Heart Journal</i> , <b>2008</b> , 156, 623-32	4.9	72

351	Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk: A Cross-Sectional Study in Chihuahua, Mexico. <i>Environmental Health Perspectives</i> , <b>2016</b> , 124, 104-11	8.4	71
350	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , <b>2016</b> , 174, 103-10	4.9	70
349	Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus. <i>Journal of Clinical Investigation</i> , <b>1991</b> , 88, 1323-30	15.9	70
348	Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. <i>Particle and Fibre Toxicology</i> , <b>2010</b> , 7, 14	8.4	68
347	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. <i>Diabetologia</i> , <b>2016</b> , 59, 1645-54	10.3	67
346	Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. <i>Diabetes Care</i> , <b>2017</b> , 40, 1034-1040	14.6	65
345	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , <b>2020</b> , 43, 1695-1703	14.6	65
344	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 82-91	6.7	65
343	Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1877-81	15.1	64
342	Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. <i>Diabetes Care</i> , <b>2016</b> , 39, 92-100	14.6	63
341	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. <i>Diabetes Care</i> , <b>2018</b> , 41, 1783-1791	14.6	63
340	Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs. <i>Science Advances</i> , <b>2019</b> , 5, eaaw4357	14.3	62
339	HEALTHY study rationale, design and methods: moderating risk of type 2 diabetes in multi-ethnic middle school students. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S4-20	5.5	60
338	We can change the natural history of type 2 diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37, 2668-76	14.6	59
337	Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 143-51	8.1	59
336	5. Prevention or Delay of Type 2 Diabetes. <i>Diabetes Care</i> , <b>2017</b> , 40, S44-S47	14.6	58
335	The GENNID Study. A resource for mapping the genes that cause NIDDM. <i>Diabetes Care</i> , <b>1996</b> , 19, 864-72	14.6	58
334	Inpatient Transition to Virtual Care During COVID-19 Pandemic. <i>Diabetes Technology and Therapeutics</i> , <b>2020</b> , 22, 444-448	8.1	55

333	COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. <i>Diabetes Care</i> , <b>2020</b> , 43, 1378-1381	14.6	55
332	Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 1247-56	6.7	54
331	Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2012</b> , 35, 955-8	14.6	53
330	Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. <i>Diabetes</i> , <b>1992</b> , 41, 1436-45	0.9	53
329	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. <i>Circulation</i> , <b>2018</b> , 137, 2179-2183	16.7	52
328	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. <i>American Heart Journal</i> , <b>2016</b> , 179, 175-83	4.9	51
327	Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. <i>Diabetes Technology and Therapeutics</i> , <b>2018</b> , 20, 571-575	8.1	50
326	Exploring salivary proteomes in edentulous patients with type 2 diabetes. <i>Molecular BioSystems</i> , <b>2012</b> , 8, 1304-10		50
325	Rationale, design and methods for process evaluation in the HEALTHY study. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S60-7	5.5	50
324	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , <b>2018</b> , 138, 2884-2894	16.7	50
323	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1798-9	59.2	48
322	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. <i>Diabetes Care</i> , <b>2014</b> , 37, 2647-59	14.6	48
321	Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. <i>Diabetes Care</i> , <b>2013</b> , 36, 429-35	14.6	47
320	Rationale, design and methods of the HEALTHY study nutrition intervention component. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S29-36	5.5	47
319	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 1763-1770	14.6	46
318	The effects of the HEALTHY study intervention on middle school student dietary intakes. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , <b>2011</b> , 8, 7	8.4	46
317	Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). <i>Diabetes/Metabolism Research and Reviews</i> , <b>2009</b> , 25, 558-65	7.5	46
316	Social marketing-based communications to integrate and support the HEALTHY study intervention. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S52-9	5.5	46

315	Combining insulin and oral agents. <i>American Journal of Medicine</i> , <b>2000</b> , 108 Suppl 6a, 23S-32S	2.4	46
314	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , <b>2018</b> , 41, 596-603	14.6	44
313	LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. <i>Pancreas</i> , <b>2014</b> , 43, 1223-31	2.6	44
312	Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. <i>Diabetologia</i> , <b>2012</b> , 55, 1641-50	10.3	44
311	Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. <i>Journal of Biological Chemistry</i> , <b>1992</b> , 267, 11673-6	5.4	44
310	Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 78-86	6.7	43
309	The insulin resistance syndrome and coronary artery disease. <i>Coronary Artery Disease</i> , <b>2003</b> , 14, 335-48	1.4	43
308	Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2019</b> , 76, 526-535	17.2	42
307	Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. <i>Diabetes Care</i> , <b>2013</b> , 36, 2162-8	14.6	42
306	Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 215-23	2.5	42
305	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 966-972	14.6	41
304	Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2203-2210	6.7	41
303	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 2229-2235	14.6	40
302	Associations between arsenic species in exfoliated urothelial cells and prevalence of diabetes among residents of Chihuahua, Mexico. <i>Environmental Health Perspectives</i> , <b>2014</b> , 122, 1088-94	8.4	40
301	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , <b>2017</b> , 187, 1-9	4.9	39
300	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 164-170	14.6	39
299	Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. <i>JAMA Ophthalmology</i> , <b>2010</b> , 128, 312-8		39
298	Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. <i>Diabetes Care</i> , <b>2017</b> , 40, 1787-1789	14.6	38

297	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1546-1552	14.6	38
296	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , <b>2019</b> , 42, 919-930	14.6	37
295	Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. <i>Endocrine Practice</i> , <b>2011</b> , 17, 906-13	3.2	37
294	The DURABILITY of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. <i>Diabetes Care</i> , <b>2011</b> , 34, 249-55	14.6	37
293	Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. <i>Transplantation</i> , <b>1993</b> , 55, 186-92	1.8	37
292	Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2116901	10.4	37
291	A survey of practices for the use of electronic health records to support research recruitment. <i>Journal of Clinical and Translational Science</i> , <b>2017</b> , 1, 246-252	0.4	35
290	Salivary proteins associated with hyperglycemia in diabetes: a proteomic analysis. <i>Molecular BioSystems</i> , <b>2013</b> , 9, 2785-97		35
289	Rationale, design and methods of the HEALTHY study behavior intervention component. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S44-51	5.5	35
288	Evaluation of the dual peroxisome proliferator-activated receptor $\alpha$ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 429-34	4.9	34
287	40 EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004. <i>Diabetologia</i> , <b>2004</b> , 47, A1-A464	10.3	34
286	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes</i> , <b>2018</b> , 67, 522-P	0.9	34
285	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 46-52	18.1	34
284	Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 395-402	6.7	33
283	Rationale, design and methods of the HEALTHY study physical education intervention component. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S37-43	5.5	33
282	Kallikrein-induced uterine contraction independent of kinin formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1981</b> , 78, 6154-7	11.5	33
281	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 2262-2272	27.4	33
280	Glucose-responsive oral insulin delivery for postprandial glycemic regulation. <i>Nano Research</i> , <b>2019</b> , 12, 1539-1545	10	33

279	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1915-1924	14.6	32
278	Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 1663-1671	14.6	32
277	Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial. <i>Pediatric Obesity</i> , <b>2012</b> , 7, 230-9	4.6	32
276	COVID-19, Hyperglycemia, and New-Onset Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 2645-2655	14.6	32
275	Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of Type 1 Diabetes Mellitus patients. <i>Clinical Immunology</i> , <b>2014</b> , 153, 156-64	9	31
274	Effect of nutrition changes on foods selected by students in a middle school-based diabetes prevention intervention program: the HEALTHY experience. <i>Journal of School Health</i> , <b>2012</b> , 82, 82-90	2.1	31
273	Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. <i>Diabetes Care</i> , <b>2013</b> , 36, 3517-25	14.6	31
272	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 446-452	14.6	31
271	Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2885-2893	6.7	31
270	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 333-340	14.6	30
269	Metabolomic characteristics of arsenic-associated diabetes in a prospective cohort in Chihuahua, Mexico. <i>Toxicological Sciences</i> , <b>2015</b> , 144, 338-46	4.4	29
268	Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 644-7	8.1	29
267	Dual self-regulated delivery of insulin and glucagon by a hybrid patch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 29512-29517	11.5	29
266	Recruitment and retention strategies and methods in the HEALTHY study. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S21-8	5.5	28
265	Lymphocyte abnormalities in the BB rat. <i>Metabolism: Clinical and Experimental</i> , <b>1983</b> , 32, 83-6	12.7	27
264	Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10744-10748	11.5	26
263	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 2000-8	14.6	26
262	Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. <i>Diabetic Medicine</i> , <b>2011</b> , 28, 715-23	3.5	26

261	The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. <i>Clinical Therapeutics</i> , <b>1998</b> , 20, 257-69	3.5	26
260	Benefits of combination of insulin degludec and liraglutide are independent of baseline glycosylated haemoglobin level and duration of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 40-8	6.7	26
259	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 138	8.7	25
258	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1128-1141	15.1	25
257	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2197-2198	5.9	25
256	HLA-A2-matched peripheral blood mononuclear cells from type 1 diabetic patients, but not nondiabetic donors, transfer insulinitis to NOD-scid/β(null)/HLA-A2 transgenic mice concurrent with the expansion of islet-specific CD8+ T cells. <i>Diabetes</i> , <b>2011</b> , 60, 1726-33	0.9	25
255	Autoimmune endocrine disease. <i>Current Opinion in Immunology</i> , <b>2002</b> , 14, 760-4	7.8	25
254	Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia. <i>Small</i> , <b>2017</b> , 13, 1603028	11	24
253	Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1223-1236	6.7	24
252	Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. <i>Diabetes Care</i> , <b>2018</b> , 41, 1998-2009	14.6	24
251	Rising temperatures explain past immigration of the thermophilic oak-inhabiting beetle <i>Coraebus florentinus</i> (Coleoptera: Buprestidae) in south-west Germany. <i>Biodiversity and Conservation</i> , <b>2013</b> , 22, 1115-1131	3.4	24
250	Prevalence of the metabolic syndrome among a racially/ethnically diverse group of U.S. eighth-grade adolescents and associations with fasting insulin and homeostasis model assessment of insulin resistance levels. <i>Diabetes Care</i> , <b>2008</b> , 31, 2020-5	14.6	23
249	Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	23
248	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1537-1547	6.7	22
247	Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-American families from the GENNID study. <i>Journal of Human Genetics</i> , <b>2012</b> , 57, 57-61	4.3	22
246	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Spectrum</i> , <b>2012</b> , 25, 154-171	1.9	22
245	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , <b>2019</b> , 170, 423-426	8	22
244	Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 712-721	6.1	20



243	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , <b>2018</b> , 138, 1605-1607	16.7	20
242	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1214-1220	16.2	20
241	Student public commitment in a school-based diabetes prevention project: impact on physical health and health behavior. <i>BMC Public Health</i> , <b>2011</b> , 11, 711	4.1	20
240	Is insulin the most effective injectable antihyperglycaemic therapy?. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 145-51	6.7	19
239	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 1912-1920	14.6	19
238	Low-density lipoprotein cholesterol versus particle number in middle school children. <i>Journal of Pediatrics</i> , <b>2013</b> , 163, 355-62	3.6	19
237	The metabolic syndrome. <i>Lancet, The</i> , <b>2005</b> , 366, 1921-2; author reply 1923-4	4.0	19
236	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , <b>2020</b> , 43, 643-652	14.6	19
235	Genetic Variants in and Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 1428-1440	0.9	18
234	Ambient PM2.5 exposure up-regulates the expression of costimulatory receptors on circulating monocytes in diabetic individuals. <i>Environmental Health Perspectives</i> , <b>2011</b> , 119, 778-83	8.4	18
233	Type 2 Diabetes Mellitus <b>2011</b> , 1371-1435		18
232	Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, e108-e110	14.6	17
231	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 1467-1470	3	17
230	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. <i>Diabetes Care</i> , <b>2018</b> , 41, 1792-1800	14.6	17
229	Should postprandial glucose be routinely measured and treated to a particular target? No!. <i>Diabetes Care</i> , <b>2003</b> , 26, 1615-8	14.6	17
228	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 970-978	6.7	16
227	Evidence supports prediabetes treatment. <i>Science</i> , <b>2019</b> , 364, 341-342	33.3	16
226	The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. <i>Journal of Diabetes and Its Complications</i> , <b>2014</b> , 28, 874-9	3.2	16

225	Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care. <i>Nature Reviews Endocrinology</i> , <b>2011</b> , 7, 67-8	15.2	16
224	Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 4273-4279	19.7	16
223	IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. <i>Journal of Diabetes Science and Technology</i> , <b>2015</b> , 10, 389-97	4.1	16
222	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 2404-2413	14.6	16
221	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. <i>Diabetes</i> , <b>2019</b> , 68, 1649-1662	0.9	15
220	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1745-1751	6.7	15
219	LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 477-86	6.7	15
218	Cardiometabolic risk assessments by body mass index z-score or waist-to-height ratio in a multiethnic sample of sixth-graders. <i>Journal of Obesity</i> , <b>2014</b> , 2014, 421658	3.7	15
217	BMI change, fitness change and cardiometabolic risk factors among 8th grade youth. <i>Pediatric Exercise Science</i> , <b>2013</b> , 25, 52-68	2	15
216	Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN rats. <i>Journal of Experimental Medicine</i> , <b>1985</b> , 162, 444-58	16.6	15
215	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e008018	6	15
214	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 1693-1702	6.9	15
213	Sodium-Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions. <i>Diabetes Care</i> , <b>2017</b> , 40, e65-e66	14.6	14
212	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1625-1633	6.7	14
211	Knowledge, awareness, and behaviors of endocrinologists and dentists for the relationship between diabetes and periodontitis. <i>Diabetes Research and Clinical Practice</i> , <b>2014</b> , 106, 428-34	7.4	14
210	Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. <i>British Journal of Psychiatry</i> , <b>2004</b> , 47, S94-101	5.4	14
209	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , <b>2015</b> , 28, 995-1009	2.3	13
208	Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. <i>Diabetes Technology and Therapeutics</i> , <b>2011</b> , 13, 601-6	8.1	13

207	A dead heat: target normal glucose levels in the intensive care unit--but with caution. <i>Diabetologia</i> , <b>2008</b> , 51, 909-10	10.3	13
206	The trials and tribulations of determining HbA targets for diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2020</b> , 16, 717-730	15.2	13
205	Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. <i>Diabetes Care</i> , <b>2021</b> , 44, 1564-1572	14.6	13
204	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 2383-2392	3.6	13
203	North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. <i>Journal of Dental Education</i> , <b>2011</b> , 75, 329-38	1.6	13
202	Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. <i>Epidemiology</i> , <b>2017</b> , 28, 446-454	3.1	12
201	Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , <b>2020</b> , 69, 771-783	0.9	12
200	Five linkage regions each harbor multiple type 2 diabetes genes in the African American subset of the GENNID Study. <i>Journal of Human Genetics</i> , <b>2013</b> , 58, 378-83	4.3	12
199	Class I, II and III major histocompatibility complex gene polymorphisms in BB rats. <i>Diabetologia</i> , <b>1984</b> , 27 Suppl, 77-9	10.3	12
198	Molecular scanning of insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. <i>Diabetes</i> , <b>1991</b> , 40, 1712-1718	0.9	12
197	Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. <i>Diabetes</i> , <b>1992</b> , 41, 1436-1445	0.9	12
196	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). <i>Diabetes Therapy</i> , <b>2020</b> , 11, 53-70	3.6	12
195	Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study. <i>International Journal of Obesity</i> , <b>2016</b> , 40, 1157-63	5.5	12
194	The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1365-1375	8.7	12
193	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCel Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009304	6	12
192	Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 505-10	6.7	11
191	Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 1065-9	6.7	11
190	Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 398-404	14.6	11

189	Real-world evidence: the devil is in the detail. <i>Diabetologia</i> , <b>2020</b> , 63, 1694-1705	10.3	11
188	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2487-2492	6.7	11
187	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 1013-23	2.8	11
186	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 525-532	6.7	11
185	Developing Insulin Delivery Devices with Glucose Responsiveness. <i>Trends in Pharmacological Sciences</i> , <b>2021</b> , 42, 31-44	13.2	11
184	Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 563-574	18.1	11
183	A Mixed-Methods, Randomized Clinical Trial to Examine Feasibility of a Mindfulness-Based Stress Management and Diabetes Risk Reduction Intervention for African Americans with Prediabetes. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2019</b> , 2019, 3962623	2.3	10
182	Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 579-584	5.7	10
181	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1217-1232	3.6	10
180	Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 129-140	6.7	10
179	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. <i>Hypertension</i> , <b>2017</b> , 70, 907-914	8.5	10
178	Late-Breaking Science Abstracts From the American Heart Association's Scientific Sessions 2017 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2017. <i>Circulation</i> , <b>2017</b> , 136, e448-e467	16.7	10
177	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. <i>Diabetes Care</i> , <b>2021</b> , 44, 1595-1603	14.6	10
176	A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 324-33	1.9	10
175	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. <i>Diabetes Care</i> , <b>2018</b> , 41, 348-355	14.6	10
174	Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 632-639	2.6	9
173	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1437-1444	6.7	9
172	Medications for type 2 diabetes: how will we be treating patients in 50 years?. <i>Diabetologia</i> , <b>2015</b> , 58, 1735-9	10.3	9

171	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2026-2034	12.3	9
170	Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 560-565	6.7	9
169	A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2689-95	2.5	9
168	Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2005</b> , 34, 221-35	5.5	9
167	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. <i>PeerJ</i> , <b>2017</b> , 5, e3187	3.1	9
166	Injectable Biodegradable Polymeric Complex for Glucose-Responsive Insulin Delivery. <i>ACS Nano</i> , <b>2021</b> , 15, 4294-4304	16.7	9
165	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. <i>Circulation</i> , <b>2020</b> , 141, 1360-1370	16.7	8
164	Longitudinal Phenotypes of Type 1 Diabetes in Youth Based on Weight and Glycemia and Their Association With Complications. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 6003-6016	5.6	8
163	Univariate and bivariate linkage analysis identifies pleiotropic loci underlying lipid levels and type 2 diabetes risk. <i>Annals of Human Genetics</i> , <b>2010</b> , 74, 308-15	2.2	8
162	Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONS). <i>Neurology</i> , <b>2009</b> , 72, 1345-51	6.5	8
161	The HEALTHY study: introduction. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S1-2	5.5	8
160	Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study. <i>Diabetes and Vascular Disease Research</i> , <b>2012</b> , 9, 124-30	3.3	8
159	Glitazones and heart failure: critical appraisal for the clinician. <i>Circulation</i> , <b>2003</b> , 108, e57	16.7	8
158	Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. <i>Diabetes Care</i> , <b>2019</b> , 42, e21-e23	14.6	8
157	The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 960-968	14.6	8
156	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , <b>2019</b> , 42, 1075-1080	14.6	7
155	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1690-1695	6.7	7
154	Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2241-2247	6.7	7

153	Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet: A Word of Caution. <i>Pediatrics</i> , <b>2018</b> , 142,	7.4	7
152	Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. <i>Metabolism: Clinical and Experimental</i> , <b>2019</b> , 98, 104-111	12.7	7
151	Effect of relative weight group change on nuclear magnetic resonance spectroscopy derived lipoprotein particle size and concentrations among adolescents. <i>Journal of Pediatrics</i> , <b>2014</b> , 164, 1091-1098.e3	3.6	7
150	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 1209-18	2.5	7
149	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 206-14	6.7	7
148	Screening for diabetes and prediabetes with proposed A1C-based diagnostic criteria: comment on Olson et al. <i>Diabetes Care</i> , <b>2010</b> , 33, e174; author reply e175	14.6	7
147	The use of insulin alone and in combination with oral agents in type 2 diabetes. <i>Primary Care - Clinics in Office Practice</i> , <b>1999</b> , 26, 931-50	2.2	7
146	Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	7
145	Comprehensive Pulmonary Safety Review of Inhaled Technosphere Insulin in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 973-983	3.2	7
144	LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. <i>Diabetology and Metabolic Syndrome</i> , <b>2016</b> , 8, 37	5.6	7
143	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. <i>Diabetes Care</i> , <b>2020</b> , 43, 940-947	14.6	6
142	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2450-2458	6.7	6
141	Effect of Secular Trends on a Primary Prevention Trial: The HEALTHY Study Experience. <i>Childhood Obesity</i> , <b>2011</b> , 7, 291-297	2.5	6
140	Clinical experience with continuous glucose monitoring in adults. <i>Diabetes Technology and Therapeutics</i> , <b>2009</b> , 11 Suppl 1, S93-S103	8.1	6
139	985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8. <i>Diabetes</i> , <b>2019</b> , 68, 985-P	0.9	6
138	Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, e32-e34	14.6	6
137	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2058-2066	6.7	6
136	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 857-866	2.6	6

135	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. <i>Diabetes Care</i> , <b>2021</b> , 44, 2729-2737	14.6	6
134	Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63 Suppl 4, 37-41	4.6	6
133	Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2096-2106	6.7	5
132	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , <b>2020</b> , 51, 276-288	4.6	5
131	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2193-2198	6.7	5
130	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). <i>Applied Health Economics and Health Policy</i> , <b>2019</b> , 17, 615-627	3.4	5
129	Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. <i>Endocrine Practice</i> , <b>2011</b> , 17, 563-7	3.2	5
128	Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. <i>Clinical Trials</i> , <b>2009</b> , 6, 416-29	2.2	5
127	What we think and what we know. <i>Diabetes Care</i> , <b>2002</b> , 25, 1876-8	14.6	5
126	Polymorphism in exon 4a of the human GLUT4/ muscle-fat facilitative glucose transporter gene detected by SSCP. <i>Nucleic Acids Research</i> , <b>1991</b> , 19, 4313	20.1	5
125	Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	5
124	Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. <i>Pharmacology Research and Perspectives</i> , <b>2020</b> , 8, e00637	3.1	5
123	Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. <i>Diabetes Care</i> , <b>2020</b> , 43, 2121-2127	14.6	5
122	Bibliometrics approach to evaluating the research impact of CTSA's: A pilot study. <i>Journal of Clinical and Translational Science</i> , <b>2020</b> , 4, 336-344	0.4	5
121	Oral Semaglutide Reduces HbA and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 1099-1116	3.6	5
120	Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 854-865	6.7	5
119	Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?. <i>Diabetes Care</i> , <b>2018</b> , 41, 1560-1562	14.6	5
118	The case for a role for postprandial glucose monitoring in diabetes management. <i>Journal of Family Practice</i> , <b>1998</b> , 47, S29-36	0.2	5

117	Disordered cellular immunity in type I diabetes of man and the BB rat. <i>Survey of Immunologic Research</i> , <b>1982</b> , 1, 339-51		5
116	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults. <i>Diabetes Care</i> , <b>2019</b> , 42, 2065-2074	14.6	4
115	Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting. <i>Diabetes Care</i> , <b>2019</b> , 42, e89-e91	14.6	4
114	Identifying individual risk rare variants using protein structure guided local tests (POINT). <i>PLoS Computational Biology</i> , <b>2019</b> , 15, e1006722	5	4
113	Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	4
112	The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. <i>Diabetes Care</i> , <b>2018</b> , 41, 1196-1203	14.6	4
111	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , <b>2016</b> , 18 Suppl 1, S43-55	8.1	4
110	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2522-2533	5.6	4
109	Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 2219-2230.e6	3.5	4
108	GLP-1 receptor agonists and basal insulin in type 2 diabetes. <i>Lancet, The</i> , <b>2014</b> , 384, 2180-1	4.0	4
107	Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 341-4	5.5	4
106	Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1996</b> , 37, 569-73	3.5	4
105	Autoimmune endocrine disease. <i>Vitamins and Hormones</i> , <b>1985</b> , 42, 253-314	2.5	4
104	Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. <i>PLoS ONE</i> , <b>2014</b> , 9, e109433	3.7	4
103	Glycemic Targets in Diabetes Care: Emerging Clarity after Accord. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2015</b> , 126, 62-76	0.9	4
102	Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1). <i>Diabetes</i> , <b>2018</b> , 67, 212-OR	0.9	4
101	21-LB: Derived Time-in-Range Is Associated with MACE in T2D: Data from the DEVOTE Trial. <i>Diabetes</i> , <b>2020</b> , 69, 21-LB	0.9	4
100	Type 1 Diabetes Mellitus <b>2011</b> , 1436-1461		4



99	Carbohydrate Intake Prior to Oral Glucose Tolerance Testing. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvab049	0.4	4
98	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS).. <i>Drugs - Real World Outcomes</i> , <b>2022</b> , 1	2.2	4
97	Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c. <i>Pediatric Diabetes</i> , <b>2019</b> , 20, 556-566	3.6	3
96	Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention. <i>Diabetes Care</i> , <b>2018</b> , 41, 1557-1559	14.6	3
95	Three approaches to glucose monitoring in non-insulin treated diabetes: a pragmatic randomized clinical trial protocol. <i>BMC Health Services Research</i> , <b>2017</b> , 17, 369	2.9	3
94	Management of glycemia in type 2 diabetes. <i>Clinical Cornerstone</i> , <b>1998</b> , 1, 39-57		3
93	Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.. <i>Circulation</i> , <b>2021</b> ,	16.7	3
92	Implementation and Evaluation of Shared Medical Appointments for Type 2 Diabetes at a Free, Student-Run Clinic in Alamance County, North Carolina <b>2018</b> , 2,		3
91	Evidence for gene-smoking interactions for hearing loss and deafness in Japanese American families. <i>Hearing Research</i> , <b>2020</b> , 387, 107875	3.9	3
90	Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1666-1671	6.7	3
89	Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1983-1988	6.7	3
88	Drug Delivery: Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery (Adv. Mater. 16/2016). <i>Advanced Materials</i> , <b>2016</b> , 28, 3223	24	3
87	Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone. <i>Diabetes Technology and Therapeutics</i> , <b>2021</b> , 23, 70-77	8.1	3
86	Diabetes educators' knowledge, opinions and behaviors regarding periodontal disease and diabetes. <i>Journal of Dental Hygiene: JDH / American Dental HygienistshAssociation</i> , <b>2012</b> , 86, 82-90	1.1	3
85	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , <b>2019</b> , 21, 682-690	8.1	2
84	New insulins and insulin therapy. <i>Diabetes Technology and Therapeutics</i> , <b>2015</b> , 17 Suppl 1, S39-46	8.1	2
83	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1732-1739	6.7	2
82	Response to comment on Hempe et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. <i>Diabetes Care</i> <b>2015</b> ;38:1067-1074. <i>Diabetes Care</i> , <b>2015</b> , 38, e172-3	14.6	2

81	Diabetes technology and treatment in the pediatric age group. <i>Diabetes Technology and Therapeutics</i> , <b>2013</b> , 15 Suppl 1, S107-16	8.1	2
80	Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , <b>2013</b> , 36, 490-490	14.6	2
79	Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1995-1996	5.1	2
78	CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. <i>Clinical and Translational Science</i> , <b>2015</b> , 8, 623-31	4.9	2
77	Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. <i>Diabetes Research and Clinical Practice</i> , <b>2012</b> , 96, e66-9	7.4	2
76	Islet Autoimmunity is Highly Prevalent and Associated With Diminished $\beta$ Cell Function in Patients With Type 2 Diabetes in the Grade Study.. <i>Diabetes</i> , <b>2022</b> ,	0.9	2
75	Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. <i>BMJ Open Diabetes Research and Care</i> , <b>2021</b> , 9,	4.5	2
74	Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2). <i>Diabetes</i> , <b>2018</b> , 67, 1179-P	0.9	2
73	Specific class II histocompatibility gene polymorphism in BB rats. <i>Diabetes</i> , <b>1984</b> , 33, 700-703	0.9	2
72	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	2
71	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2248-2256	6.7	2
70	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 810-811	18.1	2
69	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , <b>2021</b> , 38, e14552	3.5	2
68	A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. <i>Diabetes Care</i> , <b>2021</b> , 44, 1410-1418	14.6	2
67	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. <i>Frontiers in Genetics</i> , <b>2016</b> , 7, 138	4.5	2
66	More realistic power estimation for new user, active comparator studies: an empirical example. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 462-6	2.6	2
65	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. <i>Journal of Clinical and Translational Science</i> , <b>2021</b> , 5, e96	0.4	2
64	Metabolic state and gustatory perception shapes dynamic interplay between cortical excitability and motor response. <i>Brain Stimulation</i> , <b>2021</b> , 14, 202-205	5.1	2

63	Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes. <i>Diabetes Spectrum</i> , <b>2018</b> , 31, 344-347	1.9	2
62	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 723-732	6.1	2
61	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , <b>2017</b> , 40, e23-e24	14.6	1
60	Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 666-675	2.6	1
59	Bringing closure: towards achieving a better understanding of Israel. <i>Lancet, The</i> , <b>2019</b> , 394, 559	40	1
58	Évaluation des effets cardiovasculaires du liraglutide : Conception et données de base de l'étude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER <sup>®</sup> ). <i>Medecine Des Maladies Metaboliques</i> , <b>2015</b> , 9, 316-328	0.1	1
57	Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> 2019;42:1912-1920. <i>Diabetes Care</i> , <b>2020</b> , 43, e30-e31	14.6	1
56	Glucose-Responsive Systems: Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation (Adv. Mater. 13/2020). <i>Advanced Materials</i> , <b>2020</b> , 32, 2070102	24	1
55	SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES IN A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34,	4.3	1
54	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) IN A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34,	4.3	1
53	Immune intervention for type 1 diabetes, 2012-2013. <i>Diabetes Technology and Therapeutics</i> , <b>2014</b> , 16 Suppl 1, S85-91	8.1	1
52	The War Is Not Yet Won. <i>Diabetes Care</i> , <b>2017</b> , 40, 1152-1153	14.6	1
51	Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. <i>Cardiology Clinics</i> , <b>2005</b> , 23, 211-220	2.5	1
50	Should postprandial glucose be routinely measured and treated to a particular target? Connecting the two sides of the debate. <i>Diabetes Care</i> , <b>2003</b> , 26, 2700-1	14.6	1
49	T-cell antigen receptor alpha chain polymorphisms in insulin-dependent diabetes. <i>Journal of Autoimmunity</i> , <b>1988</b> , 1, 389-97	15.5	1
48	Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e022376	6	1
47	Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM: A Real-World Analysis of >700,000 U.S. Patients. <i>Diabetes</i> , <b>2018</b> , 67, 4-LB	0.9	1
46	6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL. <i>Diabetes</i> , <b>2019</b> , 68, 6-LB	0.9	1

45	957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program. <i>Diabetes</i> , <b>2020</b> , 69, 957-P	0.9	1
44	Simplici-T1 First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 126-LB	0.9	1
43	Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor. <i>Diabetes Spectrum</i> , <b>2021</b> , 34, 42-51	1.9	1
42	B-vitamins influence arsenic metabolism in Mexico. <i>FASEB Journal</i> , <b>2013</b> , 27, 1077.20	0.9	1
41	The role of obsessive-compulsive symptoms in the psychopathological profile of children with chronic tic disorder and attention-deficit hyperactivity disorder. <i>Zeitschrift für Kinder- Und Jugendpsychiatrie Und Psychotherapie</i> , <b>2013</b> , 41, 163-9; quiz 170-1	1.8	1
40	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). <i>Diabetes and Vascular Disease Research</i> , <b>2020</b> , 17, 1479164120970933 <sup>3-3</sup>	6.7	1
39	Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1677-1680	6.7	1
38	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 139-140	18.1	1
37	Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
36	Characteristics and Delivery of Diabetes Shared Medical Appointments in North Carolina. <i>North Carolina Medical Journal</i> , <b>2019</b> , 80, 261-268	0.6	1
35	Managing the risks and benefits of clinical research in response to a pandemic. <i>Journal of Clinical and Translational Science</i> , <b>2021</b> , 5,	0.4	1
34	Experimental increase of blood glucose alters resting state EEG measures of excitation-inhibition balance. <i>Experimental Physiology</i> , <b>2021</b> , 106, 803-811	2.4	1
33	Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , <b>2021</b> , 44, 2286-2292	14.6	1
32	Further RISE'ing to the Challenge of Type 2 Diabetes in Youth. <i>Diabetes Care</i> , <b>2021</b> , 44, 1934-1937	14.6	1
31	Causal role of frontal-midline theta in cognitive effort: a pilot study. <i>Journal of Neurophysiology</i> , <b>2021</b> , 126, 1221-1233	3.2	1
30	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac066	1	1
29	Reasons for Increases in Complications of Diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1518-1519	27.4	0
28	Islets Transplantation at a Crossroads - Need for Urgent Regulatory Update in the United States: Perspective Presented During the Scientific Sessions 2021 at the American Diabetes Association Congress.. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 789526	5.7	0

27	Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2132215	10.4	o
26	983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7. <i>Diabetes</i> , <b>2019</b> , 68, 983-P	0.9	o
25	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2020</b> , 34, 107706	3.2	o
24	Maria Gordon Buse, MD: A Family Affair Through Six Decades of Diabetes Discovery. <i>Diabetes Care</i> , <b>2016</b> , 39, 852-6	14.6	o
23	A new class of drug in the diabetes toolbox.. <i>Nature Medicine</i> , <b>2022</b> , 28, 901-902	50.5	o
22	New medications for the treatment of diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2015</b> , 17 Suppl 1, S119-33	8.1	
21	4300 Evaluation and structure of the pilot funding program at the University of North Carolina CTSA Hub (NC TraCS). <i>Journal of Clinical and Translational Science</i> , <b>2020</b> , 4, 72-72	0.4	
20	4299 The University of North Carolina CTSA Hub (NC TraCS) Service Evaluation: Using Customer Feedback to Improve Services. <i>Journal of Clinical and Translational Science</i> , <b>2020</b> , 4, 75-75	0.4	
19	Diabetes technology and therapy in the pediatric age group. <i>Diabetes Technology and Therapeutics</i> , <b>2014</b> , 16 Suppl 1, S100-9	8.1	
18	Concerns About Conclusions of Self-monitoring of Blood Glucose-Reply. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1874-1875	11.5	
17	Diabète et prédiabète: diagnostic et traitement <b>2011</b> , 319-326		
16	Exenatide for type 2 diabetes [Authors' reply]. <i>Lancet, The</i> , <b>2009</b> , 373, 122-123	40	
15	Are prescribing patterns of antidiabetic medications influenced by fears of litigation?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2008</b> , 4, 440-1		
14	The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement From the American Diabetes Association and the European Association for the Study of Diabetes. <i>Yearbook of Endocrinology</i> , <b>2006</b> , 2006, 40-42		
13	Latest Developments in Continuous Glucose Monitoring, Insulin, and Adjunctive Treatments in Type 1 Diabetes. <i>US Endocrinology</i> , <b>2018</b> , 14, 54	0.3	
12	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 56-OR	0.9	
11	1643-P: Prevalence of Diabetes Medication Regimens in PCORnet, the National Patient-Centered Clinical Research Network. <i>Diabetes</i> , <b>2019</b> , 68, 1643-P	0.9	
10	15-LB: Diabetes Duration Did Not Moderate the Reduction in Severe Hypoglycemia Seen with Degludec vs. Glargine U100 in DEVOTE. <i>Diabetes</i> , <b>2019</b> , 68, 15-LB	0.9	

9	1141-P: Detailed Phenotype of Randomized Participants by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes</i> , <b>2019</b> , 68, 1141-P	0.9
8	8-LB: Outcomes of Type 2 Diabetes (T2D) Clustering Replicated in the DEVOTE Trial. <i>Diabetes</i> , <b>2019</b> , 68, 8-LB	0.9
7	2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 2160-PUB	0.9
6	122-LB: The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 122-LB	0.9
5	123-LB: The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin Dose. <i>Diabetes</i> , <b>2020</b> , 69, 123-LB	0.9
4	Exposure to arsenic and cardiometabolic risk in Chihuahua, Mexico. <i>Arsenic in the Environment Proceedings</i> , <b>2014</b> , 526-530	
3	Management of Type 2 Diabetes Mellitus <b>2010</b> , 897-915	
2	Treatment of postprandial hyperglycemia in type 2 diabetes. <i>Postgraduate Medicine</i> , <b>2001</b> , 110, 14-9	3.7
1	Panel discussion on achieving glycemic control. <i>Postgraduate Medicine</i> , <b>2001</b> , 110, 20-5	3.7